Back to today’s briefing

Story perspectives

Legal Battle Over Mifepristone Intensifies Amid State Disputes

10/8/2025

40 8 Full Breakdown

Summary

Story summary

A lawsuit against the U.S. Food and Drug Administration over mifepristone remains active.
Texas Attorney General Ken Paxton's suits against out-of-state providers heighten interstate disputes over telemedicine.
Shield laws in 22 states and the District of Columbia permit mailing FDA-approved abortion pills.
Tennessee saw an 8% reduction in out-of-state abortion travel in the first half of 2025.

History

Historical Context

The 1973 Supreme Court decision in Roe v. Wade legalized abortion nationwide, affirming women's reproductive rights. However, the ruling was overturned in 2022 by Dobbs v. Jackson Women's Health Organization, prompting ongoing legal battles, including a lawsuit against the FDA over mifepristone. By 2020, 22 states had enacted shield laws, reflecting the evolving landscape of reproductive healthcare access in the U.S.

1 of 2

Story summary

A lawsuit against the U.S. Food and Drug Administration over mifepristone remains active.
Texas Attorney General Ken Paxton's suits against out-of-state providers heighten interstate disputes over telemedicine.
Shield laws in 22 states and the District of Columbia permit mailing FDA-approved abortion pills.
Tennessee saw an 8% reduction in out-of-state abortion travel in the first half of 2025.

1 / 2